Claude Miller Named President and CEO of Alpha Therapeutic Corp.Business Editors BIOWIRE2K LOS ANGELES--(BUSINESS WIRE)--Jan. 27, 2003 Alpha Therapeutic Corp. today announced that Claude Miller has been named president and chief executive officer. Edward A. Colton has assumed the position of vice chairman. In his new role, Miller will be responsible for the day-to-day operations of the company, while also focusing on strategic planning Strategic planning is an organization's process of defining its strategy, or direction, and making decisions on allocating its resources to pursue this strategy, including its capital and people. and future business development. "During his two years at Alpha, most recently as chief operating officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. , Claude Miller has spearheaded several critical corporate initiatives, including significant enhancements in manufacturing, quality control and regulatory compliance measures, and the pursuit of important new product approvals, including ARALAST(TM), Alpha-1 Proteinase proteinase /pro·tein·ase/ (pro´ten-as?) endopeptidase. pro·tein·ase n. A protease that begins the hydrolytic breakdown of proteins usually by splitting them into polypeptide chains. Inhibitor," said Yoshiharu Oda, chairman of the board of Alpha Therapeutic. Miller joined Alpha in 2000. His 20 years of experience in operations, quality assurance and regulatory affairs also includes positions at Johnson & Johnson, 3M and Genentech. Miller holds master's and bachelor's degrees in microbiology from California State University Enrollment  , Long Beach. Alpha Therapeutic, a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Welfide International Corp., Mitsubishi Pharma's U.S.-based holding company, is a leading developer of plasma-derived biopharmaceutical products. Alpha's product portfolio includes coagulation factors, immune globulin Immune globulin Serum containing antibodies against a specific infection. Mentioned in: Maternal to Fetal Infections , and albumin, which are distributed domestically to hospitals, pharmacies, home care companies and physicians. Baxter Healthcare Corp. (NYSE NYSE See: New York Stock Exchange :BAX) has been appointed exclusive distributor of ARALAST and will launch the product on behalf of Alpha. Internationally, Alpha products are marketed through a network of subsidiaries, affiliates and local offices in Asia, Europe and Latin America. Alpha is committed to providing high-quality, safe and cost-effective therapeutics for improved patient care worldwide. Additional company information is available at www.alphather.com |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion